Skip to Content

Toremifene Pregnancy and Breastfeeding Warnings

Toremifene is also known as: Fareston

Toremifene Pregnancy Warnings

In animal studies, this drug crossed the placenta and accumulated in the fetus. These studies showed doses significantly less than the daily maximum recommended human dose resulted in maternal toxicity, increased pre-implantation loss, increased resorptions, reduced fetal weight, fetal anomalies, and impairment in fertility and conception. Additionally, this drug may cause diethylstilbestrol (DES)-like effects (i.e., vaginal adenosis) in offspring like other drugs in this class. There are no controlled data in human pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

AU: Use of this drug during pregnancy is contraindicated. UK, US: Use of this drug is not recommended during pregnancy. AU TGA pregnancy category: B3 US FDA pregnancy category: D Comments: Based on its mechanism of action in humans and animal study findings of increased pregnancy loss and fetal malformation, this drug may cause fetal harm when administered to a pregnant woman.

See references

Toremifene Breastfeeding Warnings

Use of this drug is not recommended during lactation. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: In animal studies, decreased body weight gain of the offspring during lactation was observed.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.